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Abstract
Introduction: Oligodendrocytes need iron in processes of energy generation and myelination. However, excessive levels of iron may exert iron 
induced oxidative stress and thus lead to tissue degeneration. Monitoring oxidative stress will be of paramount importance in follow-up of patients 
with many diseases including multiple sclerosis (MS). The aim of this study was to measure total anti-oxidative status (TAS), total oxidative status 
(TOS) and ischemia modified albumin (IMA) in stable relapse remitting MS (RRMS) patients.
Materials and methods: Thirty-five RRMS patients (15 males and 20 females; median age 42 (20-55) years) and thirty-five age-sex matched he-
althy controls (13 males and 22 females; median age 37 (21-60) years) were included in this study. All patients were diagnosed with MS according to 
the criteria of McDonald.
Results: IMA levels were significantly higher in RRMS patients (P < 0.001), while TAS and TOS did not show any significant difference between gro-
ups (P = 0.870 and P = 0.460, respectively).
Conclusions: Our results suggest IMA as a more efficient serum marker than TAS and TOS in detecting the oxidative stress in MS patients. Serum 
oxidative stress markers should be included in future study protocols besides clinical and radiological parameters.
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Multiple sclerosis (MS) is the most prevalent neu-
rological disorder diagnosed in young adults, al-
though no age group is exempt. Approximately 
400,000 MS patients have been recorded in the 
USA and about 2.5 million worldwide, with an esti-
mated incidence of 10,000 in the United States (1). 
MS is characterized by remission and exacerba-
tions. Duration and symptoms of active disease 
vary greatly from patient to patient. Some enjoy a 
prolonged remission while others may fare poorly 
(1). The disability of such a productive population 
is the extra-motivation behind the efforts to un-
derstand and cure MS.
Pathologically, MS is characterized by death of oli-
godendrocytes, the cells engaged primarily in pro-
duction of myelin, thereby myelin loss and pres-
ence of macrophages filled with degradation end-
products. A striking feature at the lesion site dur-
ing both the acute and chronic phase of the dis-
ease is iron accumulation. Although iron accumu-
lation in the brains of MS patients has been known 
for a long time, the exact underlying mechanism is 
still obscure (2). Whether increased brain iron is the 
cause or only the consequence of a primary initiat-
ing factor is a dilemma. Independently of its 
source, free iron in a lipid rich, well oxygenated tis-
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sue means one thing: oxidative damage. The mye-
lin sheath, which is 80% lipid in composition, is ap-
parently vulnerable at the first place. Besides a 
plethora of possible causative factors, this uncom-
mon pathologic feature supports the pivotal role 
of oxidative stress in MS. The rate of production of 
oxidative substances and their destruction is in a 
state of balance in a living organism. When this 
balance is shifted towards oxidants, the new con-
dition is called oxidative stress. Although oxidative 
stress plays a role in the pathogenesis of every hu-
man disease to some extent, MS is distinctive that 
the source is evidenced by accumulated iron de-
posits detected by radiological and post-mortem 
pathologic studies (2).
Recent literature in MS seems to be dominated by 
papers dealing with rapid improvements in radio-
logical imaging procedures. Advanced MRI tech-
niques have made it possible to reliably measure 
iron content in brains of patients (3,4). Excess iron 
is a straight source of oxidative damage, and mon-
itoring the iron status in MS patients might be of 
paramount importance. Multiple studies have al-
ready found an association between iron levels 
and various measures of disease disability (5).
Besides the rapid development in radiological im-
aging procedures, serum biochemistry markers do 
still bare every advantage of feasibility and cost ef-
fectiveness. The release of the commercially avail-
able new generation ready-to-use serum marker 
kits of oxidative stress caused an explosive in-
crease in literature pertaining to the subject. “Oxi-
dative stress hunters” raced to report “impaired 
oxidative balance” in every single human disease. 
Measurements of total antioxidant status (TAS) 
and total oxidant status (TOS) can provide infor-
mation on an individual’s overall serum anti-oxida-
tive status, which may include those oxidants and 
antioxidants not yet recognized or not easily meas-
ured (6,7). Albumin is a major determinant of the 
antioxidant capacity of human serum. The mole-
cule owns the ability to bind and carry radical scav-
engers, and sequester transition metal ions with 
pro-oxidant activity besides direct anti-oxidant ca-
pabilities. The generation of reactive oxygen spe-
cies (ROS) and free radicals can transiently modify 
the N-terminal region of albumin and produce an 
increase in the concentration of ischemia modified 
albumin (IMA) (8). Recent studies present IMA as a 
marker of ischemia and oxidative stress (8,9).
After all, measuring the status of oxidative balance 
in the body might be superior to measure barely 
the iron content, as it is not the iron load but the 
oxidative damage that generates the disease. Ac-
cordingly, the aim of this study was to measure 
TAS, TOS as general markers of the oxidative status 
and IMA levels as a marker of protein modification 
due to oxidative stress in RRMS patients.
Materials and methods
Subjects
Thirty-five stable relapse remitting MS (RRMS) pa-
tients (20 females and 15 males; median age 42 
(20-55) years) admitted to the Antalya Education 
and Research Hospital were prospectively includ-
ed into the study. All patients were clinically defi-
nite MS, according to the criteria of McDonald (10). 
Clinical disability and severity were scored using 
Kurtzke’s Expanded Disability Status Scale (EDSS) 
(11). The duration of the disease was expressed in 
years from the date of neurological diagnosis. The 
progression index (PI), defined as the ratio be-
tween EDSS/MS duration, was assessed in the en-
tire MS group.
The control group consisted of thirty-five healthy 
volunteers matched for age, gender (22 females 
and 13 males; median age 37 (21-60) years), and 
geographic origin with the MS patients. Control 
subjects were without any sign or familial history 
for neurological diseases.
The patients were evaluated and diagnosed by the 
same neurologist on the basis of neurological ex-
amination. Patients with probable MS or clinical 
isolated syndrome were excluded from the study. 
In addition, those with any other acute or chronic 
inflammatory disease, anaemia, malignancy, cere-
brovascular disease, pregnancy, or patients using 
any antioxidant drugs that could influence the re-
sults, were excluded. All participants belonged to 
the same ethnic group and had comparable socio-
economic status. All subjects had a full physical 
examination and were asked to complete a gener-
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al questionnaire and gave informed consent be-
fore the onset of study. The following data were 
recorded for each patient: age, gender, medical 
history, alcohol consumption, and smoking. We 
asked for regularity in alcohol consumption. We 
defined anybody who smoked one or more ciga-
rettes per day as a smoker.
The study was approved by the local Ethical Com-
mittee and all the recruited subjects signed an in-
formed consent to participate to the study.
Samples
Blood samples were obtained after an overnight 
fasting. Five millilitres of blood from each patient 
and control was drawn into a BD Vacutainer (Bec-
ton-Dickinson, USA) SSTTM II Advance tube. Serum 
tubes are coated with micronised silica particles 
which activate clotting. Samples were checked for 
haemolysis or other interfering substances. Serum 
was then separated from the cells by centrifugation 
at 1500 x g for 10 minutes. Serum albumin was mea-
sured freshly. Remaining serum portions were stored 
at -80 °C and used to analyze TAS, TOS and IMA.
Methods
Reduced cobalt to albumin-binding capacity (IMA 
level) was measured using the rapid and colori-
metric method developed by Bar-Or et al. (8). Brief-
ly, 200 μL of patient serum was transferred into 
glass tubes and 50 μL of 0.1% CoCl2 x 6H2O (Sigma-
Aldrich, Missouri, USA) added. After gentle shak-
ing, the mixture was incubated for 10 minutes to 
ensure sufficient cobalt albumin binding. Then, 50 
μL of 1.5 mg/mL dithiothreitol (DTT) (Sigma-
Aldrich, Missouri, USA) was added as a colouring 
agent. After 2 minutes, 1 mL of 0.9% NaCl was add-
ed to halt the binding between the cobalt and al-
bumin. A blank was prepared for every specimen. 
At the DTT addition step, 50 μL of distilled water 
was used instead of 50 μL of 1.5 mg/mL DTT to ob-
tain a blank without DTT. The absorbances were 
recorded at 470 nm with a Shimadzu UV1601 spec-
trophotometer (Tokyo, Japan). Colour formation in 
specimens with DTT was compared with colour 
formation in the blank tubes, and the results were 
expressed as absorbance units (ABSU).
The inter-assay variability of IMA method in our 
laboratory was calculated from serum samples of 
20 healthy subjects and 20 patients with acute cor-
onary syndrome. The within-run coefficient of var-
iation was 1.79% for healthy subjects (mean = 
0.334; standard deviation = 0.006) and 1.62% for 
acute coronary syndrome (mean = 0.370; standard 
deviation = 0.006). IMA results should be interpret-
ed with caution when serum albumin concentra-
tions are < 20 g/L or > 55 g/L (12). The formula IMA 
value/individual serum albumin concentration was 
used to maintain the IMA rate (IMAR), in order to 
avoid the impact of albumin concentration differ-
ences between groups.
The TAS and TOS of the serum were measured by 
commercially available kits (Relassay®, Turkey) with 
an Architect ®c16000 auto analyzer (Illinois, USA), 
using an automated colorimetric measurement 
methods for both statuses developed by Erel (6,7). 
In TAS method, antioxidants in the sample reduce 
dark blue-green coloured 2,2’-azino-bis (3-ethyl-
benzthiazoline-6-sulphonic acid) (ABTS) radical to 
colourless reduced ABTS form. The change of ab-
sorbance at 660 nm is related with total antioxi-
dant level of the sample. Using this method, the 
anti-oxidative effect of the sample against the po-
tent free radical reactions initiated by the produced 
hydroxyl radical, is measured. The results are ex-
pressed as micro molar trolox equivalent per litter.
In TOS method, oxidants present in the sample ox-
idize the ferrous ion–chelator complex to ferric 
ion. The ferric ion makes a coloured complex with 
chromogen in an acidic medium. The colour inten-
sity, which can be measured spectrophotometri-
cally, is related to the total amount of oxidant mol-
ecules present in the sample. The results are ex-
pressed in terms of micro molar hydrogen perox-
ide equivalent per litter (μmol H2O2 Equiv./L).
The variability in TAS and TOS measurements in 
our laboratory was calculated in 10 serum samples. 
The within-run coefficient of variation was lower 
than 3% for both parameters (TAS 2.6%, TOS 2.9%).
Statistical analysis
Statistical analyses were carried out using the sta-
tistical software version 11.5.1.0 (MedCalc®, Mari-
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Parameters (units) Patients(N = 35)
Controls
(N = 35) P
Age (years) 38 ± 11 38 ± 10 0.800
Female, N 20 22 0.400
Smokers, N 12 13 0.600
BMI (kg/m2) 26 ± 5.3 25 ± 4.2 0.300
Duration (years) 7 ± 5 -
Disease course and 
activity All RRMS -
EDSS level 1.8 (1-5) -
Progression index (PI) 0.34 (0.04-1.2) -
Treatment
Interferon 23 -
Glatiramer acetate 9 -
No treatment 3 -
Results are shown as mean ± SD or mean and range.
N – number of individuals, BMI – body mass index, EDSS – 
expanded disability status scale.
Table 1. Demographic and clinical data of patients with MS and 
controls. The two groups were quite identical in age, gender, 
BMI and number of smokers. 
Parameters (units) Patients(N = 35)
Controls
(N = 35) P
TAS 
(nmol Troloks/L) 2.1 ± 0.2 2.1 ± 0.2 0.870
TOS 
(μmol H2O2 Equiv./L) 
0.9 ± 0.9 1 ± 0.8 0.460
IMA (ABSU) (x 10-3) 345 ± 6 335 ± 8 < 0.0001
IMAR (ABSU) (x 10-3) 82 ± 6 75 ± 5 < 0.0001
Albumin (g/L) 42 ± 0.3 45 ± 0.2 0.020
TAS - total anti-oxidative status; TOS - total oxidative status, 
IMA - ischemia modified albumin; IMAR - ischemia modified 
albumin rate (IMA/Albumin).
Table 2. Lower serum albumin in MS patients was representa-
tive of a chronic disease. IMA and IMAR measurements showed 
significant differences between RRMS group and controls. 
akerke, Belgium). Nonparametric variables were 
evaluated by using Chi-square and Fisher’s exact 
tests. Kolmogorov-Smirnov test was used to deter-
mine normality in parametric variables. All groups 
were found to be normally distributed, so the re-
sults were presented with mean and SD. The sig-
nificance of the differences between these groups 
was determined by Student’s unpaired t-test. Pear-
son correlation coefficient was used to test the 
strength of any associations between different 
variables. P values equal or less than 0.050 were 
considered statistically significant.
Results
There were no significant differences in age, gen-
der, smoking habits and body mass index (BMI) 
parameters between patients and controls. The 
patients were classified as RRMS and the disease 
duration ranged from 1 to 20 years with a mean ± 
SD of 7 ± 5 years. The scores of the EDSS ranged 
from 1 to 5 and the PI ranged from 0.04 to 1.2. The 
demographic and clinical data are summarized in 
Table 1.
Serum albumin was lower in the patient group (P 
= 0.020), reflecting the state of a chronic disease 
(Table 2). IMA levels and IMAR were significantly 
higher in RRMS patients (P < 0.001 for both) (Fig-
ure 1), while TAS and TOS did not show any signifi-
cant difference between groups (P = 0.870 and P = 
0.460, respectively) (Table 2).
Correlation analysis was used to assess correlation 
between oxidative stress markers and disease du-
ration, expanded disability status scale and pro-
gression index. There was no statistically signifi-
cant correlation between these parameters.
Discussion
IMA levels and derived IMAR were significantly 
higher in RRMS patients, while TAS and TOS levels 
between RRMS patients and our control group did 
not show a significant difference. There are at least 
two explanations that fit to our results. The MS pa-
tients in remission were as healthy as our controls 
in means of oxidative stress, and IMA results were 
non-specific or false. Or, we were unable to meas-
ure the oxidative stress in these patients with TAS 
and TOS, per contra to IMA, which showed a re-
markable difference between groups. In order to 
reach to the correct conclusion we tried to elimi-
nate one of the two proposals.
MS patient in remission may be apparently healthy, 
but even in the state of remission the accumulated 
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iron in the brain of these individuals is indolently, 
yet doggedly persistent. To appreciate the obvious 
consequences of this accumulation the basics of 
reactions between oxygen and transition metals 
should be reviewed (12). Quite a long time ago, 
when evolution has chosen a life with molecular 
oxygen, transition metals were automatically in-
cluded in the process. In nature, where transition 
metals and oxygen interfere freely, ferrous iron will 
react with molecular oxygen to produce ferric iron. 
The reaction is energetically favourable and occurs 
spontaneously. Aerobic living organisms learned 
to benefit from the addiction of oxygen to metals 
by time. However, free interaction of metal and ox-
ygen leads by-products that are destructive to or-
ganic structures. To avoid such untoward conse-
quences, transition metals are kept in cage mole-
cules like haem, chlorophyll or vitamin B12, where 
metal is fixed by coordination bonds between the 
metal and nitrogen. A free reaction is so terrifying 
that the metal in cage is also embedded in huge 
protein beds like haemoglobin. Despite all precau-
tions however, production of unwanted products, 
namely radicals, is inevitable. To cope with this in-
evitable error, which is called oxidative stress, the 
human body is equipped with a number of endog-
enous scavenging systems. Unfortunately, these 
systems have limits, and these limits get lower 
with age and certain environmental factors like 
sedentary life style or smoking (13). The body 
works on a fragile balance between production of 
oxidants and their removal. Failure of the latter is 
the way to a state of disease of any kind, depend-
ing on the background of the individual.
A disease with extreme levels of iron deposition 
may serve to comprehend the catastrophe. Tha-
lassemia patients are due to increment in serum 
and intracellular iron at extreme levels because of 
continuous blood transfusions. Due to aforemen-
tioned mechanisms, these patients are under a 
huge oxidative stress. To note, most effected or-
gans are ones with a high content mitochondria, 
the unit of oxidative energy production, and there-
by greatest sources of radical leak. Thus, it is not 
the iron accumulation but the oxidative stress it 
produces that damages the tissues. Unsurprising, 
Cakmak et al. found significantly lower TAS, TOS in 
patients with thalassemia major compared to a 
control group with P values lower than 0.0001 (14). 
There is also a problem in perception of iron con-
tent as a parameter to monitor in managing MS 
patients. To render a correct point of view, we must 
differentiate “free iron” and “iron under control” as 
components of disease initiators. From the results 
of certain studies, we understand that MS disease 
process includes at some point a shift of cellular 
iron storage from oligodendrocytes to microglia 
and macrophages. Oligodendrocytes, highly de-
pendent on iron availability for their normal func-
tionality, are known to be the major iron-contain-
ing cells in the adult CNS. Of course, the iron in oli-
godendrocytes is in strict physiologic control. 
However, iron at the site of MS lesion is kept in mi-
Figure 1. IMA levels were significantly higher in RRMS group than the controls (left). The difference was much more prominent after 
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croglia/macrophages. Indeed, iron enriched oli-
godendrocytes are a sign of healthy tissue, while 
iron-enriched microglia may indicate the presence 
of ongoing disease (2). This shift of iron from phys-
iologic to pathologic deposition is the basic of our 
assumption that measuring oxidative stress is su-
perior to mere measurements of iron load.
In a previous study, Kirbas et al. found significantly 
lower TAS and higher TOS in RRMS patients (15). 
We used the same kits as them; material and meth-
ods of both studies were quite the same. There-
fore, we do not have an explanation to the contra-
diction. Measurement of TAS and TOS are valuable, 
as they provide information about the “totals” of 
oxidants and antioxidants including the ones not 
yet recognized or not easily measured in a medi-
um. However, their “sum of all” nature is also their 
weakness, that they carry the risk of missing subtle 
changes. Thereby, these markers may fail in achiev-
ing the success they show in a disease with ex-
treme changes like thalassemia, when considering 
a disease with subtle changes like the MS in remis-
sion.
Albumin shows structural modifications in re-
spond to environmental changes in serum, includ-
ing the increase of ROS. Such modifications are not 
unique to albumin, on the contrary are basics of 
some methods of oxidative stress measurements. 
Studies that have presented higher oxidative mod-
ification of plasma proteins (16,17), higher lipid oxi-
dation products and oxide nitric metabolites 
(17,18), lower thiol levels (17,19) in MS patients com-
pared to controls. One particular study that at-
tracted our attention was by Fiorini et al. in which 
they preferred to use purified serum samples to 
measure oxidative stress markers and other pro-
teins. Their standpoint for purification was to avoid 
high abundant proteins mask the subtle changes 
in the less abundant ones. Only after purification 
they were able to detect a small but significant in-
crease in protein carbonyls as a marker of oxida-
tive stress (20).
Our discussion depends on measurements of bi-
omarkers in serum while comments on oxidative 
stress in CNS. The reader should realize that this 
limitation is also the main reason of this study, that 
feasible serum markers (easy to perform and 
cheap) may avoid more complicated and costly 
procedures like MRI or CSF sampling. Actually, oxi-
dants and antioxidants are generally permeable 
molecules, and disease states that cause a shift in 
their levels in any media will probably cause a 
comparable shift in their physiologic levels in se-
rum. The major limitations of this study were the 
small number of patients and that all our patients 
were RRMS patients. The small number of patients 
also limited measurements of the influence of 
therapy duration or type of therapy on oxidative 
stress parameters. It could also be interesting to 
add another group of patients suffering a different 
neurological disease to compare the results of 
these parameters.  
In conclusion, as we tried to describe, we strongly 
believe in the presence of oxidative stress in any 
stage of MS. We also believe in the superiority of 
measuring serum oxidative stress markers over 
sole measurements of iron load. We think TAS and 
TOS markers have failed to measure the oxidative 
stress in our patient group. However, there are 
contradictory results in other studies and the con-
tradiction is a compulsion to further studies. De-
pending on our IMA results, we hypothesize that 
there is a dynamic production of ROS in MS pa-
tients which despite of a turnover, results in an ac-
cumulation in total amount of IMA in serum of 
these patients. To prove our hypothesis, serial fol-
low-up serum IMA measurements at different 
stages of the disease are needed in order to in-
spect correlations of disease progress and levels of 
IMA. The efforts in developing clinical and imag-
ing procedures are well appreciated, but a sensi-
tive serum marker of oxidative stress is an urgent 
need in diagnosis and monitoring of these pa-
tients.
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